Polar Capital Holdings Plc Invests $50.09 Million in Savara Inc. $SVRA

Polar Capital Holdings Plc bought a new position in Savara Inc. (NASDAQ:SVRA) in the 4th quarter, HoldingsChannel.com reports. The firm bought 8,306,196 shares of the company’s stock, valued at approximately $50,086,000.

Other institutional investors also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its position in Savara by 48.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after buying an additional 3,205 shares during the period. Russell Investments Group Ltd. grew its position in Savara by 930.5% during the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares during the period. Xponance LLC bought a new position in Savara during the fourth quarter valued at about $66,000. CIBC Bancorp USA Inc. bought a new position in Savara during the third quarter valued at about $44,000. Finally, Prudential Financial Inc. bought a new position in Savara during the second quarter valued at about $30,000. Institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

SVRA has been the subject of several research reports. HC Wainwright restated a “buy” rating on shares of Savara in a research report on Monday, March 16th. William Blair set a $10.00 price target on shares of Savara in a research report on Monday, March 16th. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. Finally, Oppenheimer initiated coverage on shares of Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Savara currently has an average rating of “Moderate Buy” and an average target price of $10.14.

Savara Price Performance

NASDAQ SVRA opened at $5.30 on Wednesday. The company has a market cap of $1.09 billion, a PE ratio of -9.46 and a beta of 0.26. Savara Inc. has a 52 week low of $1.98 and a 52 week high of $7.01. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17. The firm’s 50-day simple moving average is $5.28 and its two-hundred day simple moving average is $5.60.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Research analysts predict that Savara Inc. will post -0.57 earnings per share for the current year.

Savara Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.